Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves ZYNRELEF® Vial Access Needle by Heron Therapeutics
Details : Zynrelef (bupivacaine, meloxicam) is an investigational local anesthetic given periarticularly as an extended-release solution for postoperative pain.
Product Name : Zynrelef
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2024
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Heron Submits ZYNRELEF® Vial Access Needle for FDA Approval
Details : Company submmitted Prior Approval Supplement to the FDA for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle kit.
Product Name : Zynrelef
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Heron Therapeutics Accepts Prior Approval Supplement for ZYNRELEF® Vial Access Needle
Details : Zynrelef (bupivacaine, meloxicam) is an investigational local anesthetic given periarticularly as an extended-release solution for postoperative pain. The FDA has set a PDUFA date of 23 Sep 2024.
Product Name : Zynrelef
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 07, 2024
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZYNRELEF is the first and only dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.
Product Name : Zynrelef
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 29, 2022
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprepitant
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Administered via a single 30-second IV injection, APONVIE(aprepitant) reaches drug levels associated with ≥97% receptor occupancy in the brain within five minutes and maintains therapeutic plasma concentrations for at least 48 hours.
Product Name : Cinvanti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2022
Lead Product(s) : Aprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZYNRELEF (bupivacaine) is first and only therapy for pain management to be rigorously tested demonstrated superiority to bupivacaine solution, and sustained postoperative pain relief for up to 72 hours and decreased need for opioids, with more patients o...
Product Name : Zynrelef
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 14, 2022
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New interim data from Phase 2 study suggests ZYNRELEF (bupivacaine) was well-tolerated and may effectively manage postpartum pain and minimize postoperative opioid use in women undergoing Caesarean sections.
Product Name : Zynrelef
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZYNRELEF is first and only therapy of dual-acting fixed-dose combination of local anesthetic bupivacaine and a low dose of meloxicam, for postoperative pain management to be rigorously tested in Phase 3 studies and demonstrate superiority to bupivacaine ...
Product Name : Zynrelef
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2022
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Heron Therapeutics Announces Publication of Results from HOPE Trial for ZYNRELEF™
Details : ZYNRELEF is an extended-release solution of bupivacaine and meloxicam that is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and tota...
Product Name : Zynrelef
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2021
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : J. Wood Capital Advisors
Deal Size : $150.0 million
Deal Type : Financing
Heron Therapeutics Announces $150 Million Convertible Debt Financing
Details : Proceeds from the sale of the Notes will be used for the commercial launch of ZYNRELEFTM (bupivacaine and meloxicam) extended-release solution, as well as for general working capital.
Product Name : Zynrelef
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 25, 2021
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : J. Wood Capital Advisors
Deal Size : $150.0 million
Deal Type : Financing